Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/29/2008 First Published: 12/8/2006


1.		Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV, Phase III				Treatment				Active				21 and under				Other				GPOH-NB2004 EU-20661, NCT00410631


2.		Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				MIP-IB12 NCT00458952

Last Modified: 7/17/2007 First Published: 3/24/2005


3.		Phase II Pilot Study of Targeted Radiotherapy Using Iodine I 131 Metaiodobenzylguanidine Combined With Arsenic Trioxide in Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Chromaffin Cell Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 1				Other				MSKCC-04148 NCT00107289

Last Modified: 10/2/2007 First Published: 11/4/2005


4.		Phase II Study of Iodine I 131 Metaiodobenzylguanidine and Combination Chemotherapy Comprising Carboplatin, Etoposide, and Melphalan Followed By Autologous Bone Marrow or Peripheral Blood Stem Cell Transplantation and Radiotherapy in Patients With Relapsed or Refractory Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				1 to 29				NCI				NANT-2001-02 NCT00253435

Last Modified: 9/15/2008 First Published: 4/15/2008


5.		Phase II Study of Iodine I 131 Metaiodobenzylguanidine and Autologous Stem Cell Transplantation in Young Patients With Relapsed or Refractory High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				1 to 30				NCI, Pharmaceutical / Industry				NANT-2007-01 NANT2007-01, NANT-MIP-IB13, NCT00659984, MIPI-NANT-2007-01

Last Modified: 10/2/2007 First Published: 7/24/2007


6.		Phase I Study of Irinotecan Hydrochloride, Vincristine, and Iodine I 131 Metaiodobenzylguanidine in Young Patients With Resistant or Relapsed High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				1 to 30				NCI				NANT-2004-06 NANT 2004-06, NANT-N04-06, NANT-Draximage-2007-01, NCT00509353


7.		Diagnosis of Pheochromocytoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Biomarker/Laboratory analysis, Diagnostic				Active				Not specified				NICHD				000093 00-CH-0093, NCT00004847

Last Modified: 10/2/2007 First Published: 8/30/2007


8.		Randomized Study of Standard Induction Chemotherapy Versus Topotecan Hydrochloride-Containing Induction Chemotherapy Followed by Myeloablative Autologous Stem Cell Transplantation and Consolidation Therapy With Isotretinoin in Pediatric Patients With High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Active				6 months to 21				Other				GPOH-NB2004-HR NB2004-HR, UNI-KOELN-161, NCT00526318

Select All on One Page